Episode 52: Why Is Neuroendocrine Cancer on the Rise?

Over the past several decades, neuroendocrine cancer diagnoses have increased significantly—raising an important question: Are these cancers becoming more common, or are we simply getting better at finding them? In this episode of NETWise, leading clinicians, researchers, and a patient share what the data—and real-world experience—reveal about this trend.

Drawing on insights from global experts and patient perspectives, this conversation explores how advances in imaging, pathology, and research are reshaping what we know about neuroendocrine cancer—and why earlier recognition is changing the landscape of care.

In this episode, you’ll hear about:

• Why diagnoses have risen dramatically in recent decades—and why improved detection explains much of the increase
• How modern imaging, screening, and updated classification systems are helping doctors identify tumors earlier and more accurately
• The environmental, biological, and social factors researchers are still working to understand
• Why many tumors are now discovered incidentally, before symptoms appear
• How earlier detection creates both new opportunities—and new questions—about screening and treatment decisions
• A patient’s personal story of diagnosis and how awareness can lead to earlier answers and better outcomes

As understanding grows, so does the ability to diagnose neuroendocrine cancer with greater precision—and to treat it more effectively. This episode brings clarity to what’s behind the rising numbers and what that progress means for patients and families today.

Whether you’re a patient, caregiver, clinician, or advocate, this episode offers clear, accessible insights into the breakthroughs driving research forward.

Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF’s mission to expand research, awareness, and hope across the NET community.

A special thank you to Jessica Ochoa for sharing her neuroendocrine cancer journey.